News

Virginia Catalyst Announces Round 19 of Grant Funding

The Virginia Catalyst announced today that it is accepting letters of intent (LOI) for Grant Round 19 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy.

“We at the Virginia Catalyst are pleased to provide funding in support of the Governor’s Lab-to-Launch initiative,” said Mike Grisham, CEO of Virginia Catalyst. “Collaboration between our research universities and industry drives innovations that contribute to economic development in the Commonwealth.”

We encourage those of you with innovative ideas in life sciences to reach out to colleagues and other professionals to create a high-performing team. World-class research, entrepreneurial management, and capital can achieve great things together. You have several months to get a team together and submit an LOI by January 16. We award non-dilutive grants of $200k to $800k, plus we provide great contacts with other sources of capital and strategic partnerships.

Letters of Intent (LOI) must be received by January 16, 2026, at 5:00 PM Eastern Time. Projects that meet funding criteria will be invited to submit a full application by March 20, 2026. Applications will be reviewed and scored by an independent review team of scientists, venture capitalists, and CEOs of Virginia-based life science companies. The top eight applicant teams will be invited to present their proposal in April, and awards will be announced in May 2026. The LOI submission form, along with funding criteria and frequently asked questions, are available on the Virginia Catalyst website (www.virginiacatalyst.org/apply.html).

We encourage all interested applicant teams to view our webinar that was co-hosted by Virginia Catalyst and Virginia Bio. This webinar featured an expert panel, facilitated by Mike Grisham, CEO of Virginia Catalyst, to share what it takes to score highly, get funding, and position your company and research university for significant follow-on funding from large corporations, venture capitalists, DARPA, NIH, and philanthropic foundations. This webinar can be viewed, and the slides downloaded, on the home page of Virginia Catalyst at: https://www.virginiacatalyst.org/

Cumulatively, through the first 18 funding rounds, Virginia Catalyst has dedicated a total of over $38 million for 72 collaborative projects. Together, these projects have created over 450 new jobs and have attracted nearly $900 million of investment capital from venture capital, private equity, corporations, and government agencies including DARPA, NIH, and NSF, as well as through acquisitions.

Recent News

07/15/2026

Focused Ultrasound Foundation Chairman Receives Lifetime Impact Award

Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural Lifetime Impact Award at the 2026 annual meeting of the International Society for Therapeutic Ultrasound (ISTU) in Norway in June. The award honors individuals whose work has fundamentally shaped the development, adoption, and global impact of focused ultrasound. “Dr. Kassell’s

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin